Compare fund portfolios
See how two funds' portfolios overlap. Enter two tickers:
FBT vs PBE
Shared holdings
16
FBT covered by PBE
46.45%
PBE covered by FBT
46.45%
Coverage = share of one portfolio's weight reproduced by the other (overlapping positions, min weight). Top 32 positions per side shown; = held by both — hover a shared position to highlight it in both columns.
FBT (March 31, 2026)
| Security | Weight | |
|---|---|---|
| MODERNA INC | 5.26% | |
| UNITED THERAPEUTICS CORP DEL | 4.36% | |
| ALKERMES PLC | 4.23% | |
| GILEAD SCIENCES INC | 4.09% | |
| AXSOME THERAPEUTICS INC | 3.88% | |
| AMGEN INC | 3.83% | |
| CORCEPT THERAPEUTICS INC | 3.82% | |
| KRYSTAL BIOTECH INC | 3.51% | |
| BIOGEN INC | 3.47% | |
| EXELIXIS INC | 3.46% | |
| NEUROCRINE BIOSCIENCES INC | 3.44% | |
| REGENERON PHARMACEUTICALS INC | 3.44% | |
| VERTEX PHARMACEUTICALS INC | 3.42% | |
| BIOMARIN PHARMACEUTICAL INC | 3.40% | |
| ARGENX SE SPONSORED ADR | 3.29% | |
| SAREPTA THERAPEUTICS INC | 3.24% | |
| HALOZYME THERAPEUTICS INC | 3.17% | |
| BIONTECH SE ADR | 3.16% | |
| INCYTE CORP | 3.13% | |
| BEONE MEDICINES LTD ADR | 3.12% | |
| ILLUMINA INC | 3.10% | |
| NATERA INC | 3.03% | |
| ACADIA PHARMACEUTICALS INC | 2.95% | |
| ALNYLAM PHARMACEUTICALS INC | 2.95% | |
| BIO-TECHNE CORP | 2.82% | |
| GENMAB A/S -SP ADR DEPOSITARY RECEIPT | 2.78% | |
| VERACYTE INC | 2.72% | |
| REPLIGEN CORP | 2.51% | |
| BRUKER CORP | 2.35% | |
| NEOGENOMICS INC | 2.00% | |
| DREY-GVT CSH-I | 0.06% | |
| DAIWA CAPITAL MARKETS AMERICA INC | 0.01% |
PBE (Jan. 31, 2026)
| Security | Weight | |
|---|---|---|
| Invesco Private Prime Fund | 8.92% | |
| ILLUMINA INC | 4.98% | |
| GILEAD SCIENCES INC | 4.91% | |
| AMGEN INC | 4.43% | |
| BIOGEN INC | 4.40% | |
| UNITED THERAPEUTICS CORP DEL | 4.26% | |
| REGENERON PHARMACEUTICALS INC | 4.22% | |
| INCYTE CORP | 4.08% | |
| Invesco Private Government Fund | 3.43% | |
| AMICUS THERAPEUTICS INC | 3.41% | |
| ALNYLAM PHARMACEUTICALS INC | 3.37% | |
| DYNAVAX TECHNOLOGIES CORP | 3.20% | |
| QIAGEN NV ORD SHARES | 2.68% | |
| MANNKIND CORP | 2.66% | |
| IONIS PHARMACEUTICALS INC | 2.49% | |
| ACADIA PHARMACEUTICALS INC | 2.48% | |
| ROYALTY PHARMA-A | 2.48% | |
| CATALYST PHARMACEUTICALS INC | 2.44% | |
| BIOMARIN PHARMACEUTICAL INC | 2.41% | |
| BIO-TECHNE CORP | 2.38% | |
| COLLEGIUM PHARMACEUTICAL INC | 2.38% | |
| EXELIXIS INC | 2.31% | |
| HALOZYME THERAPEUTICS INC | 2.29% | |
| BIOCRYST PHARMACEUTICALS INC | 2.27% | |
| NEUROCRINE BIOSCIENCES INC | 2.27% | |
| PTC THERAPEUTICS INC | 2.23% | |
| PROTAGONIST THERAPEUTICS INC | 2.20% | |
| VERICEL CORP | 2.19% | |
| TG THERAPEUTICS INC | 2.17% | |
| REPLIGEN CORP | 2.11% | |
| MADRIGAL PHARMACEUTICALS INC | 1.97% | |
| VERACYTE INC | 1.93% | |
| Invesco Government & Agency Portfolio, Institutional Class | 0.06% |
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.